Everest Medicines Limited

1952

KYG3224E1061

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
24.65 ^HKD	+2.28%		+14.39%	+17.94%

Apr. 25	Everest Medicines' Loss Widens in 2023	MT
Mar. 28	Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024

November 27, 2023 at 08:00 am EST

Everest Medicines reaffirms revenue guidance for the year 2023 and 2024. The company is reaffirming 2023 revenue guidance of RMB 70 million to RMB 100 million.

The company is reaffirming revenue guidance for 2024 of RMB 700 million.

Latest news about Everest Medicines Limited

Everest Medicines' Loss Widens in 2023	Apr. 24	MT
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : Everest Medicines Limited, 2023 Earnings Call, Mar 27, 2024	Mar. 27
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer	Mar. 17	CI
Everest Medicines Terminates Collaboration with Canada’s Providence for mRNA COVID-19 Vaccines	Feb. 18	MT
Everest Medicines Limited Announces Board Changes	Feb. 09	CI
Everest Foresees Surge in 2023 Revenue	Jan. 21	MT
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023	Jan. 21	CI
Everest Medicines Limited Announces Directorate Changes	Jan. 12	CI
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients	Dec. 26	CI
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China	Dec. 03	CI
Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024	Nov. 27	CI
Transcript : Everest Medicines Limited - Special Call	Nov. 27
Calliditas? Partner Everest Medicines Announces China NMPA?s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy	Nov. 24	CI
Shortened Post-Thanksgiving Session Keeps Exchange-Traded Funds, Equity Futures Muted Pre-Bell Friday	Nov. 24	MT
Calliditas Therapeutics Says Partner Secures Regulatory Approval in China for Primary IgA Nephropathy Treatment	Nov. 24	MT
Calliditas Therapeutics' Partner Secures Approval for Immunoglobulin Nephropathy Treatment in China	Nov. 24	MT
Everest Medicines Announces China NMPA's Approval of Nefecon for the Treatment of Primary IgA Nephropathy	Nov. 24	CI
Chinese Regulator Approves Everest's NDA for Nephropathy Drug	Nov. 24	MT
National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China	Nov. 23	CI
Calliditas Therapeutics' Partner Secures Approval for IgA Nephropathy Treatment in Macau	23-10-27	MT
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy	23-10-27	CI
Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients	23-09-27	CI
Sector Update: Health Care Stocks Tick Lower Thursday Morning	23-09-21	MT
North American Morning Briefing : The Post-Fed Selloff Continues	23-09-21	DJ

Chart Everest Medicines Limited

Duration

Period

More charts

Company Profile

Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.

Sector

Pharmaceuticals

Calendar

2024-06-21 - CMBIS Healthcare Virtual Corporate Day

More about the company

Income Statement Evolution

More financial data

Ratings for Everest Medicines Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

22.82 CNY

Average target price

25.92 CNY

Spread / Average Target

+13.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
EVEREST MEDICINES LIMITED	+17.94%	1.01B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals

Everest Medicines Limited

Equities

1952

KYG3224E1061

Pharmaceuticals

Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024

EPS Revisions